Lung Cancer Clinical Trials

Showing 701-720 of 2,032 trials

A Study of XZB-0004 in Patients With Solid Tumors

NCT05772455

XZB-0004 is a novel and potent small molecule inhibitor of receptor tyrosine kinase AXL. This is an open-label, multicentre phase I study of XZB-0004 in patients with solid tumors. Part 1 is a dose-escalation study to evaluate the safety, pharmacokinetic (PK), and pharmacodynamic profile of XZB-0004, and then to identify a safe and pharmacologically active dose for evaluation in subsequent cohorts or clinical studies. Part 2 is a study to evaluate the efficacy and safety of XZB-0004 combined with Penpulimab in patients with NSCLC or advanced solid tumors.

Advanced Solid TumorNSCLC

Xuanzhu Biopharmaceutical Co., Ltd.128 participantsStarted Mar 2023

Shanghai, Shanghai Municipality, China

COMPLETEDPHASE3

A Study of Tislelizumab in Combination With Chemotherapy Versus Chemotherapy in Advanced Lung Cancer

NCT03594747

An open-label, randomized, multicenter Phase 3 study designed to compare the efficacy and safety of tislelizumab combined with chemotherapy versus chemotherapy only as first-line treatment in advanced squamous non-small cell lung cancer (NSCLC).

Non-Small Cell Lung Cancer

BeiGene360 participantsStarted Jul 2018

Hefei, Anhui, China • Hefei, Anhui, China • Beijing, Beijing Municipality, China +40 more locations

A Study of XZB-0004 in Patients With Solid Tumors

A Study of Tislelizumab in Combination With Chemotherapy Versus Chemotherapy in Advanced Lung Cancer

Related Searches

Stereotactic Radiation in Patients With Small Cell Lung Cancer and 1-10 Brain Metastases

Robotic Bronchoscopy With Cone CT and Indocyanine Green to Aid Removal of Lung Lesions in Patients With Stage I Non-small Cell Lung Cancer or Lung Metastases, REPLACING Study

A Study of Atezolizumab Compared With a Single-Agent Chemotherapy in Treatment Naïve Participants With Locally Advanced or Recurrent or Metastatic Non-Small Cell Lung Cancer Who Are Deemed Unsuitable For Platinum-Doublet Chemotherapy

Imaging Study on Halcyon 4.0 System for Patients Receiving Radiation Therapy

Toripalimab and JS004 Combined With Platinum-based Chemotherapy for Relapsed and Extensive-stage Small Cell Lung Cancer

Neoadjuvant PD-1 Inhibitor (Sintilimab), Anlotinib Combined With Chemotherapy in Resectable Stage IIA-IIIB NSCLC

Milademetan in Advanced/Metastatic Solid Tumors

ARTEMIS-008：HS-20093 Compared With Topotecan in Subjects With Relapsed Small Cell Lung Cancer

Impact of Telemonitoring for the Management of Side Effects in Patients with Melanoma, Lung or Renal Cancer, Treated with Immunotherapy Combination of Nivolumab and Ipilimumab or Adjuvant Nivolumab Monotherapy

A Phase I Study of CFT8919 in Patients With Advanced NSCLC

Piloting a Virtual Navigation (VN) System for Bronchoscopic Lung Nodule Sampling

TIL Therapy Combined With Pembrolizumab for Advanced or Metastatic Refractory Lung Cancer

Comparison of Sublobar and Lobectomy in Small (2 Cm or Less 0.5<CTR<1) Non-small Cell Lung Cancer: a Prospective, Multicenter Randomized Controlled Study

Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors

DS-3201b and Irinotecan for Patients With Recurrent Small Cell Lung Cancer

Lung Cancer Screening Navigation for Homeless People

Pembrolizumab in Patients With Metastatic Non-squamous Non-small Cell Lung Cancer

Brigatinib Post Definitive Chemo-radiotherapy in Patients with ALK-fusion Non-small Cell Lung Cancer